Bio-Rad Laboratories, Inc. BIO.B Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five

Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five at other companies

State StreetSTT

$39.92B+21.5%

State StreetSTT

$3.5B-50.0%

KKR & Co.KKR

$11.7B+2.7%

State StreetSTT

$39.88B+21.1%

American International GroupAIG

$23.18B+3.2%

KKR & Co.KKR

$13.77B+27.7%

Other financials

Income statement

See full

Revenue$592.1M+1.1%

Gross profit$309.4M+1.1%

Operating income$34.1M+43.9%

Net income-$527.1M-924%

EPS (diluted)-$19.55-954%

Balance sheet

See full

Cash & equivalents$509.0M-2.7%

Total debt$987.3M-28.4%

Total equity$6.9B+2.6%

Total assets$9.8B+2.8%

Cash flow

See full

Operating cash flow$108.1M-16.8%

CapEx$30.0M-12.8%

Free cash flow$78.1M-18.2%

Valuation

See full

Market cap$7.56B+10.3%

Enterprise value$8.04B+4.2%

P/E44.8×—

P/S2.9×+0.2×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin8.8%-3.1pp

Net margin6.5%+3.4pp

FCF margin13.8%-0.2pp

Returns & leverage

See full

Return on equity2.5%+1.3pp

Debt / equity0.1×-0.1×

Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?: Bio-Rad Laboratories, Inc. (BIO.B) reported debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five of $623.1M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five changed year-over-year?: Bio-Rad Laboratories, Inc.'s debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five decreased by 9.2% year-over-year, from $686.4M to $623.1M.